Nikolaos Trikalinos
Washington University School of Medicine · Yale University Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nikolaos Trikalinos as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:45 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07842172 · Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine NeoplasmsWashington University School of Medicine · recruiting · Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm · principal investigator
- Ph2NCT06926634 · Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)Washington University School of Medicine · recruiting · High Grade Neuroendocrine Neoplasms · principal investigator
- Ph1NCT05687123 · Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsNational Cancer Institute (NCI) · recruiting · Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8 · principal investigator
- Ph2NCT04412629 · Cabozantinib in High Grade Neuroendocrine NeoplasmsWashington University School of Medicine · active not recruiting · High Grade Neuroendocrine Neoplasms · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials ConsortiumUM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · fiscal years 2014 to 2026Named on NCT05687123
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:45 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.N Engl J Med · 2025148 citationsRCR 44.0
- Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.Clin Cancer Res · 2022109 citationsRCR 7.0
- Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma.Oncologist · 202334 citationsRCR 2.5
- A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).Cancer Res Commun · 202415 citationsRCR 1.5
- FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.JAMA Oncol · 202012 citationsRCR 0.4
- A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.Cancer Chemother Pharmacol · 202110 citationsRCR 0.5
- Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer.J Immunother Cancer · 20269 citationsRCR 4.5
- Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701).Semin Oncol · 20235 citationsRCR 0.5